Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
about
Bortezomib for the treatment of mantle cell lymphoma: an updateThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?New molecular targets in mantle cell lymphomaMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsTrial Watch: Proteasomal inhibitors for anticancer therapyMantle cell lymphoma: observation to transplantationThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Current and emerging therapies in mantle cell lymphoma.Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphomaPhase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphomaA multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 studyLong-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology GroupMantle cell lymphoma activation enhances bortezomib sensitivity.Targeted therapy in lymphoma.Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma ModelPevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoMantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraA phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphomaNovel therapeutics for aggressive non-Hodgkin's lymphoma.Molecular targeted approaches in mantle cell lymphoma.Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoCombining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphomaAcquired STAT4 deficiency as a consequence of cancer chemotherapy.
P2860
Q26738940-26BB0A25-F488-43DF-800A-67086C1C9F03Q26772907-C755EF1A-2AD5-4FAA-AFE8-4CD7E1D3E0B5Q26821766-CDD25DDD-5723-4530-9AF4-258AF2528FE8Q28075606-D0A85B5D-95E7-48C8-84AC-1CAE420C47EEQ28082910-866965DF-EB73-4F7B-9ACA-58C7D155182CQ28256317-641ECEB7-C16A-4858-989B-37753019E381Q30248842-E0938728-3B5C-4F1B-9809-DB80F3B1662FQ30358639-A56C07CE-3E25-4215-A7F8-F7331B8E066DQ30456545-E38EA708-E95D-453D-A77B-0DA31E65E585Q30498194-6B08B566-0495-44C3-AC9F-FBD18D7DAF65Q33390073-BC7DBD99-A108-47F9-8C3C-00947B1EAEE1Q33394153-2B395809-564F-4AA4-B2DD-9236F9790F43Q33394689-E8121159-C6D1-4053-B493-70016E3587B2Q33394873-8A4B9625-F813-4812-8281-AAC538356545Q33396522-DCB845C2-7646-4EF0-B6D7-E4AF2310EC44Q33398818-0738EA29-EAC5-4CAD-A8CD-0B6E03C38F8AQ33399582-18F8C96C-E5FE-41C0-AEA1-D7D8EFC1C060Q33404090-ABC45FEA-C5EA-43AC-9C20-F832B4F5C67CQ33405103-D7B4CCAE-E041-4E7B-AFAB-812F941A06A7Q33410282-CE360DEF-BC46-4069-B460-FE1B063D6EC6Q33413598-A2D3F439-2533-453F-9895-BF36D307D4FDQ33832937-C6170779-03C1-4BB2-9E58-B8FE3876D549Q33893704-998D30A1-56B7-4EA6-8DFB-D6A9FA0FD7ADQ34225158-C17C1A28-B50C-42B7-96DE-0B648FA8C651Q34360347-1E7E9F08-90FB-466F-BF5C-62787E4E276AQ34413686-47ABFD4B-CA68-41DB-98C7-FB5B18DADC2CQ34465347-1AFC96CE-6D70-4BD8-BDC6-8C81C4383053Q34478543-128FE44E-00C5-45C0-8ABC-A66EA7D7A59BQ34505392-A92767A4-6653-4A45-9DE5-5555F432C3EBQ34568868-C586120D-CEFF-4A42-8A65-C96265F9B2FAQ34663617-D0ADB77F-4E5C-405C-8380-777AE2B69232Q34788381-31258FE6-3503-4690-B34F-CD831CB7B69DQ35050501-305E53AA-E61F-49D7-B868-A910511B4913Q35111768-95788D4A-A319-4D6E-9942-80ADC401F1B1Q35127368-7C5B747A-A683-49DD-9277-0F3802D621BDQ35146262-D2B095AB-5622-4F93-941D-8CDB074A8A7CQ35206717-FCB402D5-5B42-4A8A-99D1-87EE14375FD1Q35400933-4C2913EF-94E8-48EF-8ACF-F3BF36EB0FD7Q35475256-8F22A789-B1B9-44AC-8011-25528FCD02D2Q35604056-9C5F481C-7D12-41EC-A95D-894103D64014
P2860
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Bortezomib in patients with re ...... center phase 2 PINNACLE study.
@ast
Bortezomib in patients with re ...... center phase 2 PINNACLE study.
@en
type
label
Bortezomib in patients with re ...... center phase 2 PINNACLE study.
@ast
Bortezomib in patients with re ...... center phase 2 PINNACLE study.
@en
prefLabel
Bortezomib in patients with re ...... center phase 2 PINNACLE study.
@ast
Bortezomib in patients with re ...... center phase 2 PINNACLE study.
@en
P2093
P2860
P356
P1433
P1476
Bortezomib in patients with re ...... center phase 2 PINNACLE study.
@en
P2093
A Krishnan
B Djulbegovic
J P Leonard
M J Robertson
O A O'Connor
P2860
P304
P356
10.1093/ANNONC/MDN656
P577
2008-12-12T00:00:00Z